We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$881M
1-Year Est. Return
160.77%
This Fund
S&P 500
This Quarter
Est. Return
+53.48%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$244M
(+29%)
Cap. Flow
-$76.9M
Cap. Flow
% of AUM
-7.1%
Top 10 Holdings %
Top 10 Hldgs %
96.51%
Holding
17
New
1
Increased
–
Reduced
7
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Q32 Bio
QTTB
|
+$28.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dyne Therapeutics
DYN
|
+$42.2M |
| 2 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$17.6M |
| 3 |
Disc Medicine
IRON
|
+$17.4M |
| 4 |
Kymera Therapeutics
KYMR
|
+$17.2M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$8.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dyne Therapeutics
DYN
$3.37B
| $228M | 21.01% |
8,020,136
-1,865,313
| -19% | -$42.2M |
|
|
2
Kymera Therapeutics
KYMR
$9.85B
| $216M | 19.95% |
5,377,362
-480,900
| -8% | -$17.2M |
|
|
3
Disc Medicine
IRON
$2.66B
| $142M | 13.14% |
2,287,233
-267,939
| -10% | -$17.4M |
|
|
DAWN
4
DELISTED
Day One Biopharmaceuticals
DAWN
| $106M | 9.8% |
6,430,257
-1,178,137
| -15% | -$17.6M |
|
|
THRD
5
DELISTED
Third Harmonic Bio
THRD
| $103M | 9.5% |
10,907,859
| – | – |
|
6
Korro Bio
KRRO
$174M
| $101M | 9.3% |
1,119,292
| – | – |
|
|
JBIO
7
Jade Biosciences
JBIO
$1.09B
| $60.3M | 5.57% |
58,264
| – | – |
|
|
8
Q32 Bio
QTTB
$323M
| $35.6M | 3.29% |
+2,092,106
| New | +$28.8M |
|
|
GBIO
9
DELISTED
Generation Bio
GBIO
| $33.7M | 3.11% |
827,948
| – | – |
|
|
VIGL
10
DELISTED
Vigil Neuroscience
VIGL
| $19.9M | 1.84% |
5,836,874
| – | – |
|
11
Replimune Group
REPL
$1.21B
| $17.1M | 1.58% |
2,098,300
| – | – |
|
|
IMA
12
ImageneBio Inc
IMA
$57M
| $7.13M | 0.66% |
418,182
| – | – |
|
|
TECX
13
Tectonic Therapeutic
TECX
$532M
| $5.81M | 0.54% |
378,448
| – | – |
|
14
Dianthus Therapeutics
DNTH
$5.66B
| $5.61M | 0.52% |
186,979
-50,000
| -21% | -$1.09M |
|
15
Xilio Therapeutics
XLO
$59.5M
| $1.07M | 0.1% |
70,922
-126,174
| -64% | -$1.22M |
|
16
Spero Therapeutics
SPRO
$65.2M
| $1.05M | 0.1% |
607,613
-405,825
| -40% | -$636K |
|
|
AKRO
17
DELISTED
Akero Therapeutics
AKRO
| – | – |
-359,251
| Closed | -$8.39M |
|
Similar funds
AAA
FSCM
CCA
TAM
FFG
MWA
1IA
EPAM
Atlas Venture Life Science Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Atlas Venture Life Science Advisors held 17 positions worth $1.08B, up 29% from $840M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Atlas Venture Life Science Advisors withdrew a net $76.9M in Q1 2024, closing 1 position and reducing 7 holdings. Its most notable exit was Akero Therapeutics, an estimated $8.39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Atlas Venture Life Science Advisors opened a new position in Q32 Bio worth $35.6M.
- Atlas Venture Life Science Advisors's largest Q1 2024 buy was Q32 Bio: 2,092,106 shares worth $35.6M.
- Atlas Venture Life Science Advisors's biggest Q1 2024 reduction was Dyne Therapeutics, cutting an estimated $42.2M.
- Atlas Venture Life Science Advisors fully exited Akero Therapeutics in Q1 2024, selling an estimated $8.39M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 97% of its $1.08B portfolio in Q1 2024.
- Atlas Venture Life Science Advisors opened 1 new position and closed 1 in Q1 2024.
- Atlas Venture Life Science Advisors's portfolio value rose 29% quarter-over-quarter to $1.08B.
Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2024, filed 6 May 2024.